Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules

Byung Je Sung, Kwang Yeon Hwang, Young Ho Jeon, Jae Il Lee, Yong Seok Heo, Jin Hwan Kim, Jinho Moon, Jung Min Yoon, Young Lan Hyun, Eunmi Kim, Sung Jin Eum, Sam Yong Park, Jie Oh Lee, Tae Gyu Lee, Seonggu Ro, Joong Myung Cho

Research output: Contribution to journalArticlepeer-review

238 Citations (Scopus)


Phosphodiesterases (PDEs) are a superfamily of enzymes that degrade the intracellular second messengers cyclic AMP and cyclic GMP. As essential regulators of cyclic nucleotide signalling with diverse physiological functions, PDEs are drug targets for the treatment of various diseases, including heart failure, depression, asthma, inflammation and erectile dysfunction. Of the 12 PDE gene families, cGMP-specific PDE5 carries out the principal cGMP-hydrolysing activity in human corpus cavernosum tissue. It is well known as the target of sildenafil citrate (Viagra) and other similar drugs for the treatment of erectile dysfunction. Despite the pressing need to develop selective PDE inhibitors as therapeutic drugs, only the cAMP-specific PDE4 structures are currently available. Here we present the three-dimensional structures of the catalytic domain (residues 537-860) of human PDE5 complexed with the three drug molecules sildenafil, tadalafil (Cialis) and vardenafil (Levitra). These structures will provide opportunities to design potent and selective PDE inhibitors with improved pharmacological profiles.

Original languageEnglish
Pages (from-to)98-102
Number of pages5
Issue number6953
Publication statusPublished - 2003 Sept 4
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules'. Together they form a unique fingerprint.

Cite this